APL 93 Trial Results According to Induction Treatment
| . | WBC <5,000/μL and Age ≤65 . | WBC >5,000/μL . | Age >65 and WBC <5,000/μL . | P Value (log rank) . | WBC <5,000/μL and Age ≤65 . | PValue (log rank) . | |
|---|---|---|---|---|---|---|---|
| ATRA → CT . | ATRA + CT . | ||||||
| n | 208 | 163 | 42 | 109 | 99 | ||
| CR rate | 94% | 90% | 90% | .72 | 95% | 94% | .79 |
| ATRA syndrome | 16% | 18% | 10% | .40 | 20% | 11% | .17 |
| Relapse at 2 yrs | 11% | 29% | 7% | .0001 | 16% | 6% | .04 |
| Death in CR | 6.7% | 5.5% | 19% | .010 | 7% | 6% | .71 |
| EFS at 2 yrs | 80% | 69% | 67% | .0009 | 77% | 84% | .10 |
| Survival at 2 yrs | 82% | 77% | 69% | .023 | 81% | 84% | .40 |
| . | WBC <5,000/μL and Age ≤65 . | WBC >5,000/μL . | Age >65 and WBC <5,000/μL . | P Value (log rank) . | WBC <5,000/μL and Age ≤65 . | PValue (log rank) . | |
|---|---|---|---|---|---|---|---|
| ATRA → CT . | ATRA + CT . | ||||||
| n | 208 | 163 | 42 | 109 | 99 | ||
| CR rate | 94% | 90% | 90% | .72 | 95% | 94% | .79 |
| ATRA syndrome | 16% | 18% | 10% | .40 | 20% | 11% | .17 |
| Relapse at 2 yrs | 11% | 29% | 7% | .0001 | 16% | 6% | .04 |
| Death in CR | 6.7% | 5.5% | 19% | .010 | 7% | 6% | .71 |
| EFS at 2 yrs | 80% | 69% | 67% | .0009 | 77% | 84% | .10 |
| Survival at 2 yrs | 82% | 77% | 69% | .023 | 81% | 84% | .40 |